FMI
NKTR icon

F/M Investments’s Nektar Therapeutics NKTR Stock Holding History

F/M Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.23M Sell
60,585
-519
-0.8% -$38K 0.21% 86
2026
Q1 		$4.4M Buy
61,104
+2,981
+5% +$170K 0.29% 73
2025
Q4 		$2.46M Buy
58,123
+5,035
+9% +$282K 0.09% 212
2025
Q3 		$3.02M Buy
+53,088
New +$1.76M 0.12% 185

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

F/M Investments's NKTR Position: Q2 2026 in Review

F/M Investments reduced its Nektar Therapeutics (NKTR) stake by 0.85% in Q2 2026, selling an estimated $38K and leaving 60,585 shares worth $4.23M. The position accounts for 0.21% of the portfolio, ranked #86.

F/M Investments first reported a position in NKTR in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.4M in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • F/M Investments held 60,585 shares of Nektar Therapeutics worth $4.23M as of Q2 2026.
  • F/M Investments sold 519 Nektar Therapeutics shares in Q2 2026, an estimated $38K.
  • Nektar Therapeutics made up 0.21% of F/M Investments's portfolio in Q2 2026, its #86 holding.
  • F/M Investments first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • F/M Investments's Nektar Therapeutics position peaked at $4.4M in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on F/M Investments's 13F filing for Q2 2026, filed 5 Aug 2026.